SUMMARY Three patients with rapidly progressive, disseminated malignant pheochromocytoma were treated with a combination chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and dacarbazine in repeated 21-to 28-day cycles. All three patients had a marked decrease in blood pressure and an improvement in performance status within the first few cycles of treatment. At a follow-up of 6 to 13 months all patients continue to receive chemotherapy with further regression of tumor in two and stable disease in one. Their blood pressure is normal with minimal or no antiadrenergic therapy. Therapy has been well tolerated; moderate reversible granulocytopenia, neurotoxicity, and one episode of pneumonitis have been the major toxicities encountered. Thus, combination chemotherapy appears to be effective for symptomatic malignant pheochromocytoma. 1 -2 Malignant pheochromocytoma is therefore an extremely rare neoplasm, and there are few data available to guide its treatment. The experience with radiation, chemotherapy, or both, has been limited and mostly anecdotal.
3 " 8 We describe three patients with rapidly progressive, metastatic malignant pheochromocytoma who were treated successfully with a combination chemotherapy regimen. The regimen chosen was based on the published experience with the treatment of advanced stage neuroblastoma, a tumor with several pathological and biochemical features in common with malignant pheochromocytoma. *"' 2 
Methods
Three patients were shown by history, physical examination, appropriate laboratory tests, and x-ray studies to have metastatic pheochromocytoma with measurable disease that was not being irradiated. The chemotherapy regimen consisted of cyclophosphamide, 750 mg/m 2 i.v., on Day 1, vincristine, 1.4 mg/m 2 i.v., on Day 1, and dacarbazine, 600 mg/m 2 i.v., on Days 1 and 2 in 21-to 28-day cycles. Doses of cyclophosphamide and dacarbazine were increased or decreased on the basis of hematological toxicity, while that for vincristine was decreased or discontinued if neurotoxicity occurred Standard antiemetics were used as needed. Blood pressure was controlled with phenoxybenzamine and metyrosine and occasionally with prazosin, while heart rate was controlled with either propranolol or atenolol. Status of the disease was followed by measurements of plasma and/or urinary catecholamines (CA), vanillylmandelic acid (VMA), or total metanephrines (MN) every 3 weeks, and standard x-ray films or computerized tomographic (CT) scans of appropriate areas every 9 to 12 weeks. The blood pressure, heart rate, and weight were recorded at every clinic visit, and performance status was evaluated according to the Karnofsky scale, 13 a commonly used guideline to assess a patient's functional impairment (100% = normal, 10% = moribund). Pneumomtis, moderate reversible granulocytopenia BP = blood pressure, prechemo = before chemotherapy, VMA = vanillylmandclic acid.
•Normal values for urinary total metanephnnes are up to 1 3 mg/day, for VMA up to 6 8 mg/day, and for catecholamines up to 100 /d
and was thought to have pyelonephritis or nephrohthiasis. Both a renogram and an intravenous pyelogram showed a malrotated and displaced right kidney A CT scan showed a huge retroperitoneal mass in the area of the right adrenal, and a bone scan showed increased activity in the spine at C8 and LI. Urinary excretion of norepinephrine and MN were markedly elevated at 3084 /xg/day (normal, up to 100 /xg/day) and 10.7 mg/day (normal, up to 1.3 mg/day) respectively. In March 1983 he underwent operation to remove as much of the tumor as possible. Because the tumor involved the right renal artery, left renal vein, vena cava, and part of the liver, only about 50% of the total mass could be removed safely. In June 1983 he was found to have uptake of l3 'I-meta-iodobenzylguanidine ( m I-MIBG) into the remaining retroperitoneal mass, right pelvis, right midthoracic spine, and paratracheal region. He was given 186 mCi of I3 'I-MIBG, which was estimated to deliver 2000 rad to the tumor (Sisson JC, unpublished observation, 1983) . He returned home with no improvement in his symptoms, but he had a mild reduction in urinary levels of VMA, MN, and CA.
The patient was readmitted in August 1983 because of symptoms of early extradural spinal cord compression. A myelogram showed an area of marked narrowing at L1 and an area of nearly total occlusion at T8. He was immediately given high doses of dexamethasone daily and a course of x-radiation (3000 rad over 10 days) to the area from T5 to L5 Because the tumor and metastases were progressing rapidly in spite of I3I I-MIBG, it was decided to begin our proposed regimen as palliative chemotherapy. By the end of the third cycle he had marked improvement in performance status from 50 to 75%. His blood pressure was under better control with less antihypertensive medication Urinary MN and VMA levels had decreased by 30% and 63% respectively, and the size of the retroperitoneal mass had decreased by 40%. We have continued the chemotherapy since then, but there has been little further improvement in his performance status. In November 1983, while still taking dexamethasone, he had an episode of severe pneumonia, probably due to 
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Pneumocystis cannii, that responded to broad-spectrum antibiotics, including co-trimoxazole. He has also had moderate reversible granulocytopenia that was controlled by reductions of the doses of cyclophosphamide and dacarbazine. Currently, while his performance status is about 95%, and he remains on minimal antiadrenergic therapy, his urinary values of MN, VMA, and CA remain markedly elevated and his tumor masses have failed to decrease further in size. Patient 2 ( Table 2 ; Figures 2 and 3 ), a 30-year-old man, was well until September 1983 when he noted the onset of episodic headaches and hypertension. Urinary MN and VMA levels were markedly elevated at 21.3 mg/day (normal, up to 1.3 mg/day) and 65 mg/day (normal, up to 6.8 mg/day) respectively. A CT scan showed a 6.5-cm left adrenal mass as well as multiple masses in the liver and lungs. There was no uptake of I3I I-MIBG (Sisson JC, unpublished observation, 1983). Large doses of medications (phenoxybenzamine, 240 mg/day; prazosin, 15 mg/day; clonidine, 0.8 mg/day; and propranolol, 80 mg/day) were required to control his blood pressure.
On December 15, 1983 , the primary tumor and the upper pole of the left kidney, which was invaded by tumor, were resected and the liver was noted to contain many metastases distributed throughout both lobes. His blood pressure became more difficult to control, and he was transferred to the Clinical Center at the National Institutes of Health. Comparison of CT scans with those done 2 months earlier showed a rapid in- •Normal values for urinary total metanephnnes are up to 1.3 mg/day, for VMA up to 6 8 mg/day, and for catecholamines up tr 100
FIGURE 2 CT scans of lungs of Patient 2 (A) before chemotherapy (2/84) and (B) after nine cycles (9/84) Note marked reductions in size or disappearance of multiple tumor masses in the lungs
crease in the size of all metastases in the liver and lungs. Therefore, the decision was made to give him our proposed regimen as palliative chemotherapy. At the time, his plasma norepinephrine level was 53,482 pg/ml (normal, up to 390 pg/ml). Within 2 days after his first dose of chemotheiapy, mental confusion and fever associated with transient elevations of serum lactic dehydrogenase, aminotransferases, and alkaline phosphatase developed. Multiple cultures of blood, urine, and spinal fluid were all negative. The patient recently had started receiving metyrosine in an effort to control his severe hypertension. Thus, it is unclear if these symptoms were due to metyrosine toxicity or to a release of metabolic products from tumor lysis or to a combination of both. The symptoms resolved within a few days, and he recovered rapidly and felt well enough to take his second course of chemotherapy 3 weeks later He had no problems with any of the subsequent courses of chemotherapy. By the end of the third cycle of chemotherapy, he had already noted a marked improvement in performance status from 65 to 100%. His blood pressure had come under control with much reduced doses of antihypertensive medication. In addition, his urinary CA, MN, and VMA levels had fallen by 80%, 95%, and 94% respectively. The size of the prominent measurable lesions in his left lung and liver had decreased 83% and 73% respectively.
We have continued his chemotherapy now for nine courses. He continues to feel well and leads a full and active life. His blood pressure is normal on a regimen of phenoxybenzamine, 10 mg/day. Urinary levels of CA, MN, and VMA are nearly normal. We no longer see any radiolucent lesions in the liver on CT scan, and only a single 0.6 x 0.8-cm nodule remains in the left lung. His only toxicities have been the transient fever and confusion that followed Cycle 1 and moderate reversible granulocytopenia, which has been controlled by reducing the dosages of cyclophosphamide and dacarbazine.
Patient 3 (Table 3 ; Figures 4 and 5) , a 39-year-old man who had been hypertensive for 18 years, noted the onset of flank pain and hypertensive episodes in April 1981, and his urinary catecholamine levels reportedly were elevated. In August 1981a left adrenal pheochromocytoma and the involved left kidney were removed. No other tumor was noted, and he became asymptom-. atic. In December 1982, episodic hypertension returned and pulmonary nodules were seen on x-ray films In February 1983, a lung biopsy specimen showed metastatic pheochromocytoma and there was minimal uptake of I3I I-MIBG (Sisson JC, unpublished observation, 1983). In November 1983 a mass was noted in the left side of the neck. Results of a biopsy done in February 1984 confirmed that the mass was a metastatic pheochromocytoma. At this time he had moderately severe fatigue, malaise, constipation, and right upper quadrant pain. It was decided to give the patient our proposed regimen as palliative chemotherapy. By the end of the third cycle of chemotherapy, he became asymptomatic and his performance status improved from 80 to 95%. He gained weight and his blood pressure decreased from 190/104 mm Hg (phenoxybenzamine 60 mg/day) to 130/100 mm Hg (no phenoxybenzamine). There was notable regression in the palpable left supraclavicular node and in the size and number of pulmonary nodules.
We have continued his chemotherapy for eight cycles, and he remains asymptomatic. There is further regression of tumor in liver and lung. He has experienced episodes of diaphoresis, lightheadedness, and tachycardia temporally associated with the administration of chemotherapy. These symptoms last several days and are not associated with any changes in blood pressure. The patient has also had moderate reversible granulocytopenia and neurotoxicity, which resulted in the discontinuation of vincristine.
Discussion
Each of the three patients was markedly symptomatic as a result of rapidly progressive, widely disseminated disease. Patients 1 and 2 also had substantial side effects from the drugs required to control their severe hypertension. Pretherapy performance status was only 1-22 Diaphoresis, lightheadedness, extremity numbness, impotence, nausea and vomiting, moderate reversible granulocytopenia BP = blood pressure; prechemo = before chemotherapy, VMA = vanillylmandehc acid
•Normal values for urinary total metanephnnes are up to 1 3 mg/day. for VMA up to 6 8 mg/day, and for catecholamines up to 100 /xg/day 50%, 65%, and 80% respectively. Each patient had considerable improvement in his sense of well-being, weight, and muscular strength at the end of the first few cycles, and all patients are nearly asymptomatic at the present time. Blood pressure, which was hard to control before chemotherapy (average, 192/108 mm Hg), has either returned to normal or been easier to control (average, 133/89 mm Hg). At the same time, the doses of medicines needed to control hypertension and tachycardia have decreased appreciably (e.g., phenoxybenzamine, doses before chemotherapy. 160, 240, and 60 mg/day respectively, compared with 20, 10, and 50 mg/day currently). Similarly, the dosage of metyrosine went from 1500 mg/day to none in Patient 1, and from 2000 mg/day to none in Patient 2. Some tumor masses seen on x-ray film or CT scan disappeared entirely (liver mass in Patients 2 and 3; see Figures 3 and 5) , while others showed 40 to 60% reductions in size (retroperitoneal mass in Patient 1 and lung in Patient 3; see Figures 1 and 4) , and a few remained unchanged (paratracheal mass, Patient 1). All three patients remain on a regimen of chemotherapy with evidence of further tumor regression in Patients 2 and 3 and stable disease in Patient 1.
Therefore, a combination chemotherapeutic regimen of cyclophosphamide, vincnstine, and dacarbazine given in 21-to 28-day cycles was beneficial in the treatment of three patients with malignant pheochromocytoma. There was no uptake of 13I I-MIBG in two of them (Patients 2 and 3), and the tumor was progressing rapidly in spite of I3 'I-MIBG treatment in the third (Patient 1).
A review of the literature yielded only eight reports of chemotherapy in a total of 12 patients with malignant pheochromocytoma (Table 4) . 3 4 7 8 Cyclophosphamide was the most frequently used drug, alone or in combination, in 9 of the 12 patients; 5 had palliation. Vincnstine was used in 5 of the 12, and 3 had palliation. Combination chemotherapy was used in 
FIGURE 4 CT scans of lungs of Patient 3 (A) before chemotherapy (2/84) and (B) after eight cycles (8/84). Note marked reduction in size of all the numerous tumor masses in both lungs
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FIGURE 5 CT scans of abdomen of Patient 3 (A) before chemotherapy (2/84) and (B) after eight cycles (8184) Note disappearance of multiple, large radiolucenl lesions in the liver.
of the 12 patients, and most of the 12 patients had received concomitant radiation therapy. A review of the literature on radiation therapy for malignant pheochromocytoma (Table 5 )^ yielded data on 44 patients treated since 1960. In general, xradiation therapy has provided relief of pain and stopped progression of some bony lesions. The response of soft tissue lesions has been disappointing. More recently, Sisson et al. 3 have used I3I I-MIBG to treat five patients, but only two showed objective response as measured by tumor size and catecholamine secretion. Vetteret al. 6 have reported two patients with minor reduction in tumor size but no change in secretion of catecholamines following I3 'I-MIBG. In our own experience, we have found that only one of five patients with malignant pheochromocytoma has had appreciable uptake of I3I I-MIBG into the tumor. Thus, we could not use radiation therapy and we lacked background information from previous treatment of malignant pheochromocytomas on which to base our chemotherapy.
There are many similarities between pheochromocytoma and neuroblastoma: (1) both arise from a primitive neural crest cell (sympathogonium), (2) both metastasize to lymph nodes, bone, liver, and lung, (3) both secrete catecholamines, and (4) both contain the neurochemical marker neuron-specific enolase as well as neurosecretory granules and a prominent rough endoplasmic reticulum. 9 Because of these similarities and because there are good data on chemotherapy for Hamilton etal. 7 Scott et al. Scott et al. 4 Vetter et al. 6 Sisson et al This combination chemotherapeutic regimen has produced a nearly complete response in Patient 2 and a partial response in Patients 1 and 3. Patient 2 continues to improve, and we plan to continue therapy in all three patients until (1) there are no more signs of disease, as measured on x-ray film or CT scan and by increased amounts of catecholamines or metabolites in plasma or urine, or (2) there is obvious growth of tumor or new metastases in spite of chemotherapy.
Toxicity has not been a serious problem. Malaise, nausea, and vomiting have been limited to the 48 hours following administration of chemotherapy and have been reasonably well controlled with prochlorperazine, metoclopramide, thiethylperazine, droperidol, and dexamethasone as needed. Reversible granulocytopenia has been moderate and controlled by reduction of dosages of cyclophosphamide and dacarbazine as needed One instance of pneumonitis occurred while Patient 1 was taking glucocorticoids; however, this responded promptly to therapy with broad-spectrum antibiotics, including co-tnmoxazole. Patient 2 had a toxic metabolic syndrome during his first course of chemotherapy. Patient 3 has had episodes of tachycardia, diaphoresis, and lightheadedness related to the administration of chemotherapy. Recently, Patient 1 has had acute episodes of sweating and hypertension during administration of chemotherapy. These episodes appear to be related to catecholamine release and respond to increased doses of phenoxybenzamine. Hypertensive crises following cytotoxic drug therapy in patients with unsuspected pheochromocytomas have been reported previously.
14 -" In our experience, acute lysis of tumor with the release of large amounts of catecholamines and resultant severe hypertension is not a problem as long as the patients have adequate a-adrenergic blockade.
Although we have shown beneficial effects of combination chemotherapy in patients with rapidly progressive symptomatic malignant pheochromocytoma, the number of patients reported here is too small to make any definite recommendations for the treatment of this disease. In addition, we do not have any data on whether or not this regimen would be effective for pheochromocytomas that are progressing slowly. Furthermore, the toxicity of this regimen in this patient population remains to be defined. Thus, we are currently conducting a prospective trial of combination chemotherapy in patients with malignant pheochromocytoma.
